Eisai Co. Ltd. v. Mylan Pharmaceuticals Inc.
1:13-cv-01282
Overview
Parties
Defendant
Mylan Pharmaceuticals Inc. Operating Company
Represented By
7 Attorneys ListedPotter Anderson & Corroon, LLP
1313 N. Market St., Hercules Plaza, 6th Flr., P.O. Box 951
Potter Anderson & Corroon, LLP
1313 N. Market St., Hercules Plaza, 6th Flr., P.O. Box 951
Plaintiff
Novartis Pharma AG Operating Company
Represented By
2 Attorneys ListedMorris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Morris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Eisai Inc. Operating Company
Represented By
2 Attorneys ListedMorris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Morris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Eisai Co. Ltd. Operating Company
Represented By
2 Attorneys ListedMorris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Morris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Court & Judges
Court
District Court, D. Delaware (ded)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360Β° Radar 6 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| πΊπΈ United States | US 6,740,669 Asserted | Asserted Patent | View Official Patent → |
| πΊπΈ United States | US 2003012556 | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 2004016718 | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 7,750,028 B2 | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 8,076,362 B2 | US Continuation / Sibling | View Official Patent → |
| π PCT International (WIPO) | WO 1998056772 A1 | PCT World Application | View Official Patent → |
No active co-pending lawsuits found across other jurisdictions for this family. All related sibling filings are currently unlitigated.
Patents Involved
There are 3 patents involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US6740669
Crystal modification of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide and its use as antiepileptic
|
Filed: 1998-06-08
Issued: 2004-05-25
|
Expired (Term Ended)
+801d PTA
Expires: 2020-08-17
|
|
|
US7750028
Crystal modifications of 1-(2,6-difluorobenzyl)-1H-1, 2,3-triazole-4-carboxamide
|
Filed: 2006-01-11
Issued: 2010-07-06
|
Expired (Term Ended)
Expires: 2018-10-19
|
|
|
US8076362
Crystal modification A of 1-(2,6-difluorobenzyI)-1 H-1,2,3-triazole-4-carboxamide and dosage forms and formulations thereof
|
Filed: 2010-04-26
Issued: 2011-12-13
|
Active (3.4 yrs remaining)
Expires: 2030-04-26
|
Patent Enforceability & Injunction Risk Assessment
Statutorily Barred β Patent expired. Under 35 U.S.C. Β§ 283, courts cannot grant an injunction once a patent's term concludes. Litigation is restricted exclusively to past damages lookback.
High PTA (+801 days) / Cellect Scrutiny β Over 801 days of PTA awarded. Susceptible to In re Cellect double patenting invalidation if continuation patents in the same family expire earlier.
Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).
Procedural Motions & Interlocutory Orders
Total Motions
5
Dispositive
0
Granted
0
Denied
0
Pending / Review
3
Motions by Category
Key Dispositive Motions & Rulings